Polyclonal antibody hyperGAMCF

Drug Profile

Polyclonal antibody hyperGAMCF

Latest Information Update: 10 Jul 1996

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Antibacterials; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 10 Jul 1996 Discontinued-II for Pseudomonal infections in USA (IV)
  • 10 Jul 1996 North American Biologicals is now called NABI
  • 10 Jul 1996 Discontinued-II for Cystic fibrosis-associated respiratory tract infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top